Abstract
Since its introduction, vaccinology has been very effective in controlling and eliminating life-threatening infectious diseases. However, in several cases, the conventional approach to identifying protective antigens, based on biochemical, immunological, and microbiological methods, has failed to deliver successful vaccine candidates against major human pathogens. The availability of complete bacterial genome sequences has allowed scientists to change the paradigm and approach vaccine development starting from genomic information, a process named reverse vaccinology. This can be considered as one of the most powerful examples of how genomic information can be used to develop vaccines that were difficult or impossible to tackle with conventional approaches. The ever-growing genomic data, the new genome-based approaches and high-throughput sequencing technologies will help to complement reverse vaccinology to enable timely development of new vaccine antigens against emerging infectious diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Fleischmann RD et al (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269(5223):496–512
Medini D et al (2008) Microbiology in the post-genomic era. Nat Rev Microbiol 6(6):419–430
Raskin DM et al (2006) Bacterial genomics and pathogen evolution. Cell 124(4):703–714
Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17–19):2688–2691
Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369(9580):2196–2210
Caugant DA, Maiden MC (2009) Meningococcal carriage and disease—population biology and evolution. Vaccine 27(suppl 2):B64–B70
Tettelin H et al (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459):1809–1815
Pizza M et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816–1820
Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 23(17–18):2222–2227
Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129(6):1307–1326
Serruto D et al (2010) Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 107(8):3770–3775
Masignani V et al (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197(6):789–799
Seib KL et al (2009) Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77(1):292–299
Capecchi B et al (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55(3):687–698
Comanducci M et al (2002) NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195(11):1445–1454
Giuliani MM et al (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103(29):10834–10839
Kimura A et al (2011) Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 18(3):483–486
Findlow J et al (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51(10):1127–1137
Snape MD et al (2010) Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 29(12):e80–e90
Johri AK et al (2006) Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 4(12):932–942
Tettelin H et al (2002) Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 99(19):12391–12396
Tettelin H et al (2005) Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci USA 102(39):13950–13955
Maione D et al (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309(5731):148–150
Lauer P et al (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309(5731):105
Rosini R et al (2006) Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 61(1):126–141
Margarit I et al (2009) Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199(1):108–115
Brzuszkiewicz E et al (2006) How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc Natl Acad Sci USA 103(34):12879–12884
Hain T et al (2007) Pathogenomics of Listeria spp. Int J Med Microbiol 297(7–8):541–557
Perrin A et al (2002) Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect Immun 70(12):7063–7072
Perrin A, Nassif X, Tinsley C (1999) Identification of regions of the chromosome of Neisseria meningitidis and Neisseria gonorrhoeae which are specific to the pathogenic Neisseria species. Infect Immun 67(11):6119–6129
Moriel DG et al (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA 107(20):9072–9077
Madico G et al (2007) Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J Immunol 178(7):4489–4497
Schneider MC et al (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15(5):233–240
Telford JL et al (2006) Pili in gram-positive pathogens. Nat Rev Microbiol 4(7):509–519
Barocchi MA et al (2006) A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 103(8):2857–2862
Mora M et al (2005) Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci USA 102(43):15641–15646
Adu-Bobie J et al (2003) Two years into reverse vaccinology. Vaccine 21(7–8):605–610
Bambini S et al (2009) Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27(21):2794–2803
Donnelly J et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 107(45):19490–19495
Telford JL (2008) Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3(6):408–416
Hall N (2007) Advanced sequencing technologies and their wider impact in microbiology. J Exp Biol 210(Pt 9):1518–1525
Schuster SC (2008) Next-generation sequencing transforms today's biology. Nat Methods 5(1):16–18
Margulies M et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057):376–380
Bennett ST et al (2005) Toward the 1,000 dollars human genome. Pharmacogenomics 6(4):373–382
Shendure J et al (2005) Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309(5741):1728–1732
Ansorge WJ (2009) Next-generation DNA sequencing techniques. N Biotechnol 25(4):195–203
Metzker ML (2010) Sequencing technologies—the next generation. Nat Rev Genet 11(1):31–46
Harris SR et al (2010) Evolution of MRSA during hospital transmission and intercontinental spread. Science 327(5964):469–474
Croucher NJ et al (2011) Rapid pneumococcal evolution in response to clinical interventions. Science 331(6016):430–434
Grifantini R et al (2002) Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 20(9):914–921
Wizemann TM et al (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69(3):1593–1598
Hoskins J et al (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 183(19):5709–5717
Etz H et al (2002) Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99(10):6573–6578
Vytvytska O et al (2002) Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2(5):580–590
Ross BC et al (2001) Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19(30):4135–4142
Hughes MJ et al (2002) Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 70(3):1254–1259
Reid SD et al (2002) Postgenomic analysis of four novel antigens of group a streptococcus: growth phase-dependent gene transcription and human serologic response. J Bacteriol 184(22):6316–6324
Rodriguez-Ortega MJ et al (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24(2):191–197
Montigiani S et al (2002) Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70(1):368–379
Berlanda Scorza F et al (2008) Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics 7(3):473–485
Serruto D et al (2004) Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 113(1–3):15–32
Sorek R, Cossart P (2010) Prokaryotic transcriptomics: a new view on regulation, physiology and pathogenicity. Nat Rev Genet 11(1):9–16
Croucher NJ, Thomson NR (2010) Studying bacterial transcriptomes using RNA-seq. Curr Opin Microbiol 13(5):619–624
Yoder-Himes DR et al (2009) Mapping the Burkholderia cenocepacia niche response via high-throughput sequencing. Proc Natl Acad Sci USA 106(10):3976–3981
Perkins TT et al (2009) A strand-specific RNA-Seq analysis of the transcriptome of the typhoid bacillus Salmonella typhi. PLoS Genet 5(7):e1000569
Mraheil MA et al (2011) The intracellular sRNA transcriptome of Listeria monocytogenes during growth in macrophages. Nucleic Acids Res 39(10):4235–4248
Passalacqua KD et al (2009) Structure and complexity of a bacterial transcriptome. J Bacteriol 191(10):3203–3211
Camarena L et al (2010) Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog 6(4):e1000834
Albrecht M et al (2010) Deep sequencing-based discovery of the Chlamydia trachomatis transcriptome. Nucleic Acids Res 38(3):868–877
Sharma CM et al (2010) The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 464(7286):250–255
Mahan MJ, Slauch JM, Mekalanos JJ (1993) Selection of bacterial virulence genes that are specifically induced in host tissues. Science 259(5095):686–688
Hensel M et al (1995) Simultaneous identification of bacterial virulence genes by negative selection. Science 269(5222):400–403
Sun YH et al (2000) Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 6(11):1269–1273
van Opijnen T, Bodi KL, Camilli A (2009) Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat Methods 6(10):767–772
van Opijnen, T. and A. Camilli, Genome-wide fitness and genetic interactions determined by Tn-seq, a high-throughput massively parallel sequencing method for microorganisms. Curr Protoc Microbiol, 2010. Chapter 1: p. Unit1E 3.
Langridge GC et al (2009) Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. Genome Res 19(12):2308–2316
Gawronski JD et al (2009) Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for Haemophilus genes required in the lung. Proc Natl Acad Sci USA 106(38):16422–16427
Rappuoli R (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10(11): 1177–85
Granoff DM et al. (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77(2): 764–9
Metruccio MM et al (2009) A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 5(12): e1000710
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cafardi, V., Telford, J.L., Serruto, D. (2013). Bacterial Genomes and Vaccine Design. In: Flower, D., Perrie, Y. (eds) Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. Immunomics Reviews:, vol 5. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5070-2_2
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5070-2_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5069-6
Online ISBN: 978-1-4614-5070-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)